Essa Pharma INC DEF 14A proxy statements

ESSA Pharma Inc. is facing a putative class action lawsuit alleging breach of contract and promissory estoppel related to disclosures made prior to its announced business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. announced an amended Interim Order from the Supreme Court of British Columbia, confirming key dates for its Special Meeting and court hearing related to the business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. has amended its business combination agreement, reducing the immediate cash payout to shareholders while increasing the contingent value rights due to a Nasdaq trading issue.

ESSA Pharma Inc. has amended its business combination agreement, increasing the contingent value right component and contingent reserve due to new potential liabilities, while maintaining the expected upfront cash payment.

ESSA Pharma Inc. has amended its business combination agreement with XenoTherapeutics, reducing the upfront cash payment to shareholders and introducing a contingent value right.

ESSA Pharma Inc. has adjourned its special meeting to approve the XenoTherapeutics acquisition, citing ongoing discussions for revised financial terms.

ESSA Pharma Inc. clarified the due bill trading period for its US$80 million capital distribution, stating shares traded ex-dividend from August 25, 2025, correcting an earlier announcement.

ESSA Pharma Inc. announced the ex-dividend date and due bill trading procedures for its US$80 million return of capital distribution as part of its winding-up and acquisition by XenoTherapeutics.

ESSA Pharma Inc. shareholders are invited to vote on a proposed acquisition by Xeno Acquisition Corp. for cash and contingent value rights, following the discontinuation of its clinical trials and business winding-up.

ESSA Pharma Inc. announced an $80 million capital distribution to shareholders ahead of its acquisition by XenoTherapeutics, with total expected shareholder proceeds of approximately $1.91 per share.

ESSA Pharma Inc. has mailed a letter to shareholders outlining the potential U.S. and Canadian federal income tax consequences of a cash distribution related to its business combination with XenoTherapeutics, Inc.

ESSA Pharma Inc. announced its intent to apply to the Supreme Court of British Columbia for an interim order to hold a special meeting and authorize an initial cash distribution to shareholders prior to the closing of its business combination with XenoTherapeutics, Inc.

ESSA Pharma Inc. announces a definitive agreement to be acquired by XenoTherapeutics, Inc. through a plan of arrangement, offering shareholders a cash payment and contingent value rights.

ESSA Pharma Inc. has entered into a definitive agreement to be acquired by XenoTherapeutics, Inc., backed by XOMA Royalty Corporation, in an all-cash transaction that includes contingent value rights for shareholders, as ESSA winds down its operations.

ESSA Pharma Inc. will hold its annual general meeting on March 5, 2025, with shareholders voting on key proposals including the election of directors and appointment of auditors.

ESSA Pharma Inc. will hold its annual general meeting on March 5, 2025, to address key items including director elections, executive compensation, and auditor appointment.